HIV care and treatment for children in resource-limited settings

References

• Fowler MG, Lampe MA, Jamieson DJ, Kourtis AP, Rogers MF. Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions. Am. J. Obstet. Gynecol.197(3 Suppl.), S3–S9 (2007).
   PubMed Web of Science ®Google Scholar
• Lallemant M, Jourdain G, Le Coeur S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med.351(3), 217–228 (2004).
   PubMed Web of Science ®Google Scholar
• Stover J, Bollinger L, Walker N, Monasch R. Resource needs to support orphans and vulnerable children in sub-Saharan Africa. Health Policy Plan22(1), 21–27 (2007).
   PubMed Web of Science ®Google Scholar
• De Baets AJ, Bulterys M, Abrams EJ, Kankassa C, Pazvakavambwa IE. Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level. Pediatr. Infect. Dis. J.26(2), 163–173 (2007).
   PubMed Web of Science ®Google Scholar
• Kline MW. Perspectives on the pediatric HIV/AIDS pandemic: catalyzing access of children to care and treatment. Pediatrics117(4), 1388–1393 (2006).
   PubMed Web of Science ®Google Scholar
• Terra de Souza AC, Peterson KE, Andrade FM, Gardner J, Ascherio A. Circumstances of post-neonatal deaths in Ceara, Northeast Brazil: mothers’ health care-seeking behaviors during their infants’ fatal illness. Soc. Sci. Med.51(11), 1675–1693 (2000).
   PubMedGoogle Scholar
• English M, Esamai F, Wasunna A et al. Assessment of inpatient paediatric care in first referral level hospitals in 13 districts in Kenya. Lancet363(9425), 1948–1953 (2004).
   PubMed Web of Science ®Google Scholar
• Luo C, Akwara P, Ngongo N et al. Global progress in PMTCT and paediatric HIV care and treatment in low- and middle-income countries in 2004–2005. Reprod. Health Matters15(30), 179–189 (2007).
   PubMed Web of Science ®Google Scholar
• KoberK, Van Damme W. Scaling up access to antiretroviral treatment in southern Africa: who will do the job? Lancet364(9428), 103–107 (2004).
   PubMed Web of Science ®Google Scholar
• Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet370(9581), 68–80 (2007).
   PubMed Web of Science ®Google Scholar
• Ooms G, Van Damme W, Temmerman M. Medicines without doctors: why the Global Fund must fund salaries of health workers to expand AIDS treatment. PLoS Med.4(4), e128 (2007).
   PubMed Web of Science ®Google Scholar
• Eley B, Davies MA, Apolles P et al. Antiretroviral treatment for children. S. Afr. Med. J.96(9 Pt 2), 988–993 (2006).
   PubMed Web of Science ®Google Scholar
• George E, Noel F, Bois G et al. Antiretroviral therapy for HIV-1-infected children in Haiti. J. Infect. Dis.195(10), 1411–1418 (2007).
   PubMed Web of Science ®Google Scholar
• Marazzi MC, Germano P, Liotta G et al. Pediatric highly active antiretroviral therapy in Mozambique: an integrated model of care. Minerva Pediatr.58(5), 483–490 (2006).
   PubMedGoogle Scholar
• Myung P, Pugatch D, Brady MF et al. Directly observed highly active antiretroviral therapy for HIV-infected children in Cambodia. Am. J. Public Health97(6), 974–977 (2007).
   PubMedGoogle Scholar
• O’Brien DP, Sauvageot D, Zachariah R, Humblet P. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS20(15), 1955–1960 (2006).
   PubMed Web of Science ®Google Scholar
• Puthanakit T, Oberdorfer A, Akarathum N et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand’s National Access to Antiretroviral Program. Clin. Infect. Dis.41(1), 100–107 (2005).
   PubMed Web of Science ®Google Scholar
• Reddi A, Leeper SC, Grobler AC et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr.7, 13 (2007).
   PubMedGoogle Scholar
• Walker AS, Mulenga V, Ford D et al. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin. Infect. Dis.44(10), 1361–1367 (2007).
   PubMed Web of Science ®Google Scholar
• Tumwesigye N, Kieffer M, Marquis B et al. Response to antiretroviral therapy (ART) in children in sub-Saharan Africa: the KIDS-ART-LINC collaboration multicentre pooled analysis. Presented at: HIV/AIDS Implementers’ Meeting. Kigali, Rwanda, 16–19 June 2007.
   Google Scholar
• Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA298(16), 1888–1899 (2007).
   PubMed Web of Science ®Google Scholar
• van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect. Dis.2(2), 93–102 (2002).
   PubMed Web of Science ®Google Scholar
• de Martino M, Tovo PA, Balducci M et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA284(2), 190–197 (2000).
   PubMed Web of Science ®Google Scholar
• Jean SS, Pape JW, Verdier RI et al. The natural history of human immunodeficiency virus 1 infection in Haitian infants. Pediatr. Infect. Dis. J.18(1), 58–63 (1999).
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Sauvageot D, Olson D et al. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin. Infect. Dis.44(9), 1245–1248 (2007).
   PubMedGoogle Scholar
• Bong CN, Yu JK, Chiang HC et al. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi. AIDS21(13), 1805–1810 (2007).
   PubMed Web of Science ®Google Scholar
• Wamalwa DC, Farquhar C, Obimbo EM et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J. Acquir. Immune Defic. Syndr.45(3), 311–317 (2007).
   PubMed Web of Science ®Google Scholar
• Kamya MR, Mayanja-Kizza H, Kambugu A et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J. Acquir. Immune Defic. Syndr.46(2), 187–193 (2007).
   PubMed Web of Science ®Google Scholar
• Natu SA, Daga SR. Antiretroviral therapy in children: Indian experience. Indian Pediatr.44(5), 339–343 (2007).
   PubMed Web of Science ®Google Scholar
• Colebunders R, Ronald A, Katabira E, Sande M. Rolling out antiretrovirals in Africa: there are still challenges ahead. Clin. Infect. Dis.41(3), 386–389 (2005).
   PubMedGoogle Scholar
• Ponnet M, Frederix K, Petdachai W et al. A drug dosage table is a useful tool to facilitate prescriptions of antiretroviral drugs for children in Thailand. Int. J. STD AIDS16(6), 420–426 (2005).
   PubMedGoogle Scholar
• Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet361(9376), 2226–2234 (2003).
   PubMed Web of Science ®Google Scholar
• Spira R, Lepage P, Msellati P et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics104(5), e56 (1999).
   PubMed Web of Science ®Google Scholar
• Mphatswe W, Blanckenberg N, Tudor-Williams G et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS21(10), 1253–1261 (2007).
   PubMed Web of Science ®Google Scholar
• Newell ML, Coovadia H, Cortina-Borja M et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet364(9441), 1236–1243 (2004).
   PubMed Web of Science ®Google Scholar
• Vermund SH. Prevention of mother-to-child transmission of HIV in Africa. Top. HIV Med.12(5), 130–134 (2004).
   PubMedGoogle Scholar
• Sherman GG, Matsebula TC, Jones SA. Is early HIV testing of infants in poorly resourced prevention of mother to child transmission programmes unaffordable? Trop. Med. Int. Health10(11), 1108–1113 (2005).
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Hoblitzelle CW, Sripipatana TL, Wilfert CM. Provision of care following prevention of mother-to-child HIV transmission services in resource-limited settings. AIDS21(18), 2529–2532 (2007).
   PubMed Web of Science ®Google Scholar
• Sherman GG, Jones SA, Coovadia AH, Urban MF, Bolton KD. PMTCT from research to reality – results from a routine service. S. Afr. Med. J.94(4), 289–292 (2004).
   PubMed Web of Science ®Google Scholar
• Manzi M, Zachariah R, Teck R et al. High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop. Med. Int. Health10(12), 1242–1250 (2005).
   PubMed Web of Science ®Google Scholar
• Chintu C, Bhat GJ, Walker AS et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet364(9448), 1865–1871 (2004).
   PubMed Web of Science ®Google Scholar
• Panakitsuwan S, Yoshihara N, Hashimoto N, Miyamura K, Chotpitayasunondh T. Early diagnosis of vertical HIV infection in infants by rapid detection of immune complex-dissociated HIV p24 antigen. AIDS Patient Care STDS11(6), 429–433 (1997).
   PubMed Web of Science ®Google Scholar
• Fiscus SA, Wiener J, Abrams EJ et al. Ultrasensitive p24 antigen assay for diagnosis of perinatal human immunodeficiency virus type 1 infection. J. Clin. Microbiol.45(7), 2274–2277 (2007).
   PubMed Web of Science ®Google Scholar
• Violari A, Cotton M, Gibb D et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22–25 July 2007.
   Google Scholar
• Siva N. Treating HIV-infected infants early prolongs life. Lancet Infect. Dis.7(9), 573 (2007).
   PubMedGoogle Scholar
• Kessler L, Daley H, Malenga G, Graham S. The impact of the human immunodeficiency virus type 1 on the management of severe malnutrition in Malawi. Ann. Trop. Paediatr.20(1), 50–56 (2000).
   PubMed Web of Science ®Google Scholar
• Bachou H, Tumwine JK, Mwadime RK, Tylleskar T. Risk factors in hospital deaths in severely malnourished children in Kampala, Uganda. BMC Pediatr.6, 7 (2006).
   PubMedGoogle Scholar
• Amadi B, Kelly P, Mwiya M et al. Intestinal and systemic infection, HIV, and mortality in Zambian children with persistent diarrhea and malnutrition. J. Pediatr. Gastroenterol. Nutr.32(5), 550–554 (2001).
   PubMed Web of Science ®Google Scholar
• Zar HJ. Global paediatric pulmonology: out of Africa. Paediatr. Respir. Rev.7(Suppl. 1), S226–S228 (2006).
   PubMed Web of Science ®Google Scholar
• Zachariah R, Harries AD, Luo C, Bachman G, Graham SM. Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. Lancet Infect. Dis.7(10), 686–693 (2007).
   PubMedGoogle Scholar
• Anglaret X, Messou E, Ouassa T et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d’Ivoire. AIDS17(4), 575–584 (2003).
   PubMed Web of Science ®Google Scholar
• Thera MA, Sehdev PS, Coulibaly D et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J. Infect. Dis.192(10), 1823–1829 (2005).
   PubMed Web of Science ®Google Scholar
• Williams PL, Storm D, Montepiedra G et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics118(6), e1745–e1757 (2006).
   PubMed Web of Science ®Google Scholar
• Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet367(9513), 817–824 (2006).
   PubMed Web of Science ®Google Scholar
• Bikaako-Kajura W, Luyirika E, Purcell DW et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav.10(4 Suppl.) S85–S93 (2006).
   PubMed Web of Science ®Google Scholar
• Rabie H, de Boer A, van den Bos S et al. Children with human immunodeficiency virus infection admitted to a paediatric intensive care unit in South Africa. J. Trop. Pediatr.53(4), 270–273 (2007).
   PubMedGoogle Scholar
• Callens S, Kokolomami J, Kitetele F et al. Improving survival of children living with HIV in resource poor settings requires a comprehensive programmatic response. Presented at: AIDS 2006 – XVI International AIDS Conference. Toronto, Canada, 13–18 August 2006.
   Google Scholar
• The Malawi Paediatric ART group. Antiretroviral therapy for children in the routine setting in Malawi. Trans. R Soc. Trop. Med. Hyg.101(5), 511–516 (2007).
   PubMedGoogle Scholar
• Ellis JC, L’homme RFA, Ewings F et al. Nevirapine concentrations in HIV-infected children treated with divided fixed dose combinationantiretroviral tablets in Malawi and Zambia. Antiviral Therapy12(2), 253–260 (2007).
   PubMed Web of Science ®Google Scholar
• Ambrus JL Sr, Ambrus JL Jr. Nutrition and infectious diseases in developing countries and problems of acquired immunodeficiency syndrome. Exp. Biol. Med. (Maywood)229(6), 464–472 (2004).
   PubMed Web of Science ®Google Scholar
• Weidle PJ, Abrams EJ, Gvetadze R, Rivadeneira E, Kline MW. A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings. Pediatr. Infect. Dis. J.25(1), 59–64 (2006).
   PubMed Web of Science ®Google Scholar
• Flys TS, Donnell D, Mwatha A et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J. Infect. Dis.195(5), 711–715 (2007).
   PubMed Web of Science ®Google Scholar
• Arrive E, Newell ML, Ekouevi DK et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol.36(5), 1009–1021 (2007).
   PubMed Web of Science ®Google Scholar
• Chi BH, Sinkala M, Stringer EM et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS21(8), 957–964 (2007).
   PubMed Web of Science ®Google Scholar
• Puthanakit T, Oberdorfer A, Akarathum N et al. Effectiveness of NNRTI-based HAART in ART-naive HIV-infected children participating in Thailand’s National Access Program: 72-week result. Presented at: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22–25 February 2005.
   Google Scholar
• Machado DM, Fernandes SC, Succi RC et al. Analysis of HIV-type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART). Rev. Inst. Med. Trop. Sao Paulo47(1), 1–5 (2005).
   PubMedGoogle Scholar
• Flynn PM, Rudy BJ, Douglas SD et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J. Infect. Dis.190(2), 271–279 (2004).
   PubMed Web of Science ®Google Scholar
• Walker AS, Doerholt K, Sharland M, Gibb DM. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS18(14), 1915–1924 (2004).
   PubMed Web of Science ®Google Scholar
• Chiappini E, Galli L, Zazzi M, de Martino M. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy. J. Med. Virol.70(4), 506–512 (2003).
   PubMedGoogle Scholar
• de Martino M, Galli L, Moriondo M et al. Dissociation of responses to highly active antiretroviral therapy: notwithstanding virologic failure and virus drug resistance, both CD4+ and CD8+ T lymphocytes recover in HIV-1 perinatally infected children. J. Acquir. Immune Defic. Syndr.26(2), 196–197 (2001).
   PubMedGoogle Scholar
• Donald PR. Childhood tuberculosis: out of control? Curr. Opin. Pulm. Med.8(3), 178–182 (2002).
   PubMed Web of Science ®Google Scholar
• Liebeschuetz S, Bamber S, Ewer K et al. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet364(9452), 2196–2203 (2004).
   PubMed Web of Science ®Google Scholar
• Cotton MF, Schaaf HS, Hesseling AC, Madhi SA. HIV and childhood tuberculosis: the way forward. Int. J. Tuberc. Lung Dis.8(5), 675–682 (2004).
   PubMedGoogle Scholar
• van Rheenen P. The use of the paediatric tuberculosis score chart in an HIV-endemic area. Trop. Med. Int. Health7(5), 435–441 (2002).
   PubMedGoogle Scholar
• Chintu C, Mwaba P. Tuberculosis in children with human immunodeficiency virus infection. Int. J. Tuberc. Lung. Dis.9(5), 477–484 (2005).
   PubMed Web of Science ®Google Scholar
• Detjen AK, Keil T, Roll S et al. Interferonγrelease assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin. Infect. Dis45(3), 322–328 (2007).
   PubMed Web of Science ®Google Scholar
• RenY, Nuttall J, Egbers C et al. Plasma concentrations of efavirenz and lopinavir in children with and without rifampicin-based anti-TB treatment. Presented at: 14th Conference On Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007.
   Google Scholar
• Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int. J. Tuberc. Lung Dis.9(3), 248–257 (2005).
   PubMed Web of Science ®Google Scholar
• French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS18(12), 1615–1627 (2004).
   PubMed Web of Science ®Google Scholar
• Zar HJ, Cotton MF, Strauss S et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. Br. Med. J.334(7585), 136 (2007).
   PubMed Web of Science ®Google Scholar
• Krause JC, Toye MP, Stechenberg BW, Reiter EO, Allen HF. HIV – associated lipodystrophy in children. Pediatr. Endocrinol. Rev.3(1), 45–51 (2005).
   PubMedGoogle Scholar
• Aurpibul L, Puthanakit T, Lee B et al. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir. Ther.12(8), 1247–1254 (2007).
   PubMed Web of Science ®Google Scholar
• van Griensven J, De Naeyer L, Mushi T et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans. R Soc. Trop. Med. Hyg.101(8), 793–798 (2007).
   PubMed Web of Science ®Google Scholar
• Leonard EG, McComsey GA. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Infect. Dis. Clin. North Am.19(3), 713–729 (2005).
   PubMedGoogle Scholar
• Tahan TT, Bruck I, Burger M, Cruz CR. Neurological profile and neurodevelopment of 88 children infected with HIV and 84 seroreverter children followed from 1995 to 2002. Braz. J. Infect. Dis.10(5), 322–326 (2006).
   PubMedGoogle Scholar
• Van Rie A, Harrington PR, Dow A, Robertson K. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: a global perspective. Eur. J. Paediatr. Neurol.11(1), 1–9 (2007).
   PubMed Web of Science ®Google Scholar
• Martin SC, Wolters PL, Toledo-Tamula MA et al. Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART). Dev. Neuropsychol.30(2), 633–657 (2006).
   PubMed Web of Science ®Google Scholar
• Lindsey JC, Malee KM, Brouwers P, Hughes MD. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. Pediatrics119(3), e681–e693 (2007).
   PubMed Web of Science ®Google Scholar
• Boivin MJ, Green SD, Davies AG et al. A preliminary evaluation of the cognitive and motor effects of pediatric HIV infection in Zairian children. Health Psychol14(1), 13–21 (1995).
   PubMed Web of Science ®Google Scholar
• Gutierrez JP, Johns B, Adam T et al. Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost? Lancet364(9428), 63–64 (2004).
   PubMed Web of Science ®Google Scholar